News

A new Phase 3 clinical trial (NCT02697734) is actively recruiting Cushing’s disease patients in several countries to test the safety and effectiveness of the investigational therapy osilodrostat (LCI699). The 48-week, multicenter, randomized, double-blind, placebo-controlled study is sponsored by Novartis Pharmaceuticals. Estimated enrollment is 69 patients at 26 locations…

The recent identification of genetic mutations linked to Cushing disease (CD) and its unbalanced molecular mechanisms has opened new potential therapeutic avenues for an illness with a large unmet medical need. In the study, “Recent advances in understanding Cushing disease: resistance to…

Signifor (pasireotide), an approved therapy for Cushing’s disease, has shown promise as a long-term treatment for some patients with the disease, according to results of an extension study of a Phase 3 clinical trial (NCT00434148). These findings were published recently…

Aggressive adrenocortical carcinomas differ from tumors linked to Cushing’s syndrome in the density of blood and lymph vessels, according to a research team at Portugal’s University of Porto. Their study, “Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors,” appeared in the journal Pathology & Oncology Research. It offers insights into the…

Mutations in a gene called CABLES1 might contribute to pituitary tumor growth in people with Cushing’s disease, according to a study that suggests the gene normally acts as a pituitary tumor suppressor. The study, “Loss-of-function mutations in the…

Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…

The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…